Skip to main content
×
×
Home

Perceptions and knowledge of antipsychotics among mental health professionals and patients

  • Lindah Cahling (a1), Anders Berntsson (a1), Gabriella Bröms (a2) and Lars Öhrmalm (a1) (a2)
Abstract
Aims and method

To assess the patients' most influential concerns regarding long-acting injectable antipsychotics (LAIs) and mental health professionals' preconceptions about these concerns. For both groups, to assess the level of knowledge about LAIs. This cross-sectional study used semi-structured interviews of patients with schizophrenia or schizoaffective disorder (n = 164), nurses (n = 43) and physicians (n = 20).

Results

The mental health professionals overestimated many of the patients' fears of LAIs, and the expressed fears exceeded the actual experiences of patients already on LAIs. Acceptance to switch to LAIs was associated with shorter time from diagnosis. Nurses and patients disclosed limited knowledge of antipsychotics.

Clinical implications

Physicians and nurses should aim to identify the individual patient's concerns about LAIs in the discussion about choice of antipsychotic treatment early in the course of illness.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Perceptions and knowledge of antipsychotics among mental health professionals and patients
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Perceptions and knowledge of antipsychotics among mental health professionals and patients
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Perceptions and knowledge of antipsychotics among mental health professionals and patients
      Available formats
      ×
Copyright
This is an open-access article published by the Royal College of Psychiatrists and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
lars.ohrmalm@prima.se
Footnotes
Hide All

Declaration of interest

L.Ö. has received speaker honoraria from Otsuka Pharma Scandinavia AB and H. Lundbeck AB, and has accepted travel and hospitality payment from Otsuka Pharma Scandinavia AB.

Footnotes
References
Hide All
1 Weiden, PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007; 68 (suppl 14): 14–9.
2 Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886–91.
3 Subotnik, KL, Nuechterlein, KH, Ventura, J, Gitlin, MJ, Marder, S, Mintz, J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168: 286–92.
4 Heres, S, Lambert, M, Vauth, R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 2014; 29 (suppl 2): 1409–13.
5 Marcus, SC, Zummo, J, Pettit, AR, Stoddard, J, Doshi, JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015; 21: 754–68.
6 Kirson, NY, Weiden, PJ, Yermakov, S, Huang, W, Samuelson, T, Offord, SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013; 74: 568–75.
7 Dencker, SJ. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry 1984; 45: 22–7.
8 Gerlach, J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9 (suppl 5): 1720.
9 Agid, O, Foussias, G, Remington, G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010; 11: 2301–17.
10 Waddell, L, Taylor, M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; suppl. 52: S4350.
11 Patel, MX, De Zoysa, N, Bernadt, M, David, A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009; 23: 789–96.
12 Weiden, PJ, Roma, RS, Velligan, Dl, Alphs, L, DiChiara, M, Davidson, B. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry 2015; 76: 684–90.
13 Beitinger, R, Kissling, W, Hamann, J. Trends and perspectives of shared decision-making in schizophrenia and related disorders. Curr Opin Psychiatry 2014; 27: 222–9.
14 Potkin, S, Bera, R, Zubek, D, Lau, G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013; 13: 261.
15 Das, AK, Malik, A, Haddad, PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol 2014; 4: 179–85.
16 Patel, MX, Haddad, PM, Chaudhry, IB, McLoughlin, S, Husain, N, David, AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010; 24: 1473–82.
17 James, BO, Omoaregba, JO, Okonoda, KM, Otefe, EU, Patel, MX. The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria. Ther Adv Psychopharmacol 2012; 2: 169–77.
18 Subotnik, KL, Casaus, LR, Ventura, J, Luo, JS, Helleman, GS, Gretchen-Doorly, D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry 2015; 72: 822–9.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 2056-4694
  • EISSN: 2056-4708
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 31 *
Loading metrics...

Abstract views

Total abstract views: 107 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 23rd June 2018. This data will be updated every 24 hours.

Perceptions and knowledge of antipsychotics among mental health professionals and patients

  • Lindah Cahling (a1), Anders Berntsson (a1), Gabriella Bröms (a2) and Lars Öhrmalm (a1) (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *